Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy.

Dal Molin, Graziela Z; Omatsu, Kohei; Sood, Anil K; Coleman, Robert L

Dal Molin, Graziela Z; Omatsu, Kohei; Sood, Anil K; Coleman, Robert L.

Afiliação

Dal Molin GZ; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Omatsu K; Department of Gynecology, The Cancer Institute Hospital, Tokyo, Japan.
Sood AK; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Coleman RL; Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas, MD Anderson Cancer Center, 1155 Herman Pressler Drive, CPB 6.3590, Houston, TX 77030, USA.

Ther Adv Med Oncol ; 10: 1758835918778483, 2018.

Article em En | MEDLINE | ID: mdl-29977351

Palavras-chave

BRCA; PARP; PARP inhibitors; Rubraca; ovarian cancer; platinum-sensitive ovarian cancer; rucaparib

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Outros_tipos Base de dados: MEDLINE Idioma: En Revista: Ther Adv Med Oncol Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google